Replies to post #392396 on Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

Because the "Research was performed by scientists at George Mason University’s Center for Infectious Disease Research (formerly NCBID)."
https://www.ipharminc.com/press-release/2022/6/28/innovation-pharmaceuticals-announces-new-antiviral-research-on-brilacidin-in-bunyaviruses-and-alphaviruses-to-be-presented-at-the-2022-military-health-system-research-symposium

I expect someone from this organization to make the presentation.

From the same press release "A review article is being prepared on Brilacidin based on this research and on results from the Company’s Phase 2 clinical trial (NCT04784897) of intravenous Brilacidin in moderate-to-severe hospitalized cases of COVID-19." It is possible Dr. DeGrado will be an author for this review article.

https://www.ipharminc.com/new-blog/2022/3/15/scientific-advisor-william-f-degrado-gives-keynote-lecture-at-2021-faraday-discussion-also-co-awarded-the-2020-john-scott-medal?rq=DeGrado

https://www.ipharminc.com/press-release/2020/8/26/dr-william-f-degrado-a-discoverer-of-brilacidin-joins-innovation-pharmaceuticals-as-scientific-advisor?rq=DeGrado